Inhibitors of c-jun-N-Terminal Kinase (JNK)

Authors: LoGrasso, Philip; Kamenecka, Theodore

Source: Mini Reviews in Medicinal Chemistry, Volume 8, Number 8, July 2008 , pp. 755-766(12)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.

Keywords: c-jun-N-Terminal Kinase (JNK); mitogen activated protein (MAP); benzothiazole pyrimidines; benzothien-2-yl amides; indazoles; aminopyrimidines; aminopyridines; quinolines

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138955708784912120

Publication date: 2008-07-01

More about this publication?

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.